2029 Leads Patients Safety 
European Pharmaceutical Review
JUNE 16, 2023
According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.
Pharmaceutical Technology
JANUARY 10, 2023
Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in 2029, although its sales growth is likely to continue beyond 2029.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 26, 2023
Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.
Medico Reach
OCTOBER 17, 2022
However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.
Medico Reach
OCTOBER 17, 2022
However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.
Expert insights. Personalized for you.
102 
Let's personalize your content